Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Scientific Prices €1.2B Senior Notes Offering

NEW YORK – Thermo Fisher Scientific said on Monday that it has priced an offering of €1.2 billion ($1.33 billion) worth of euro-denominated senior notes.

The Waltham, Massachusetts-based company is offering €6 billion worth of senior notes with an interest rate of 1.75 percent per year and a due date of 2027, and €6 billion worth of senior notes with an interest rate of 2.375 percent per year and a due date of 2032.

The offering is expected to close on or about April 2, subject to customary closing conditions, and the notes will pay interest on an annual basis.

Thermo Fisher plans to use the proceeds of the offering to pay in part for the $11.5 billion acquisition of Qiagen, expected to close in the first half of 2021, including paying back Qiagen's debt. It also intends to use the proceeds for general corporate purposes, such as the acquisition of companies, the repayment and refinancing of debt, working capital and capital expenditures, and the repurchase of outstanding equity securities.

JP Morgan Securities, Morgan Stanley International, Merrill Lynch International, and Citigroup Global are joint book-running managers for the offering, as well as Credit Suisse Securities (Europe), MUFG Securities EMEA, and US Bankcorp Investments for the 2027 notes, and BNP Paribas, HSBC Bank, and SMBC Nikko Capital Markets for the 2032 notes.

The new offering comes a week after Thermo Fisher offered a total of $2.2 billion worth of senior notes, due in 2025 and 2030.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more